



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Chaetocin

Catalog #: 27221

Lot #: 120626


Size: 1 mg

Structure:

CAS Registry #: 28097-03-2

Purity: ≥95%

Chemical Formula: C₃₀H₂₈N₆O₆S₄



Molecular Weight: 696.8

Description: Chaetocin is an inhibitor of histone methyltransferases (HMTs) including SUV39H1 and Lys9-specific HMTs such as G9a. It also has some inhibitory effects on SET7, EZH2, and SET7/9. Chaetocin has also been shown to induce cellular oxidative stress, and as a result, cancer cells are selectively killed and primary cells rapidly proliferate. It is a fungal myotoxin. The inhibitor is useful in epigenetics and cancer research.

Appearance: A crystalline solid

Solubility: Soluble in organic solvents purged with an inert gas and solubility is 25 mg/ml. Do not store aqueous solutions for more than one day.

Biological Activity: Chaetocin inhibits SUV39H1 with an IC₅₀ = 0.8 μM, G9a with an IC₅₀ = 2.5 μM, and DIM5 with an IC₅₀ = 3 μM.

Storage/Stability: Store at or below -20°C for up to two years.

Quality Control: The purity was determined by HPLC analysis.

References:

1. Greiner, D., *et al.*, *Nat. Chem. Biol.* 2005;**1(3)**:143-145.
2. Isham, C.R., *et al.*, *Blood* 2007;**109(6)**:2579-2588.
3. Tibodeau, J.D., *et al.*, *Antioxid. Redox Signal.* 2009;**11(5)**:1097-1106.
4. Spannhoff, A., *et al.*, *Int. J. Biochem. Cell Biol.* 2009;**41**:4-11.
5. Copeland, R.A., *et al.*, *Nat. Rev. Drug Discov.* 2009;**8**:724-732.